الفهرس 
Introduction and Aims of the StudyOnly 14 pages are availabe for public view
 |  | from | 133 |  |  |
| | | from | 133 | | |
Abstract
Thalidomide has an immunomodulatory impact, by providing stimulation of T cells. Common adverse effects of thalidomide included fatigue, somnolence, constipation, fluid retention, neuropathy, venous thromboembolic disease (VTD) and rash. As a result of the promising activity of thalidomide, synthetic analogues were established and launched to provide equivalent or superior immunomodulation but with a reduced toxicity profile. Carboplatin has myelosuppressive impact This affects the blood cell and platelet output of bone marrow in the body to reduce quite significantly. Common adverse effects of carboplatin including diarrhea, hair loss, mouth sores, nausea, vomiting, fatigue, infection, aches, pains, numbness and tingling.
Chemotherapeutic drugs have been presented to produce oxidative stress by the raise of lipid peroxidation products, the decrease of total radical-trapping capacity of blood plasma, the decrease in plasma levels of antioxidants such as vitamin E, vitamin C, and p-carotene and the obvious reduction of tissue glutathione levels that happens through chemotherapy. Antioxidant supplements are useful in combining with chemotherapy because they improve the efficiency of the chemotherapeutic agents, in addition to relieve toxic adverse effects, permitting patients to tolerate chemotherapeutic drugs for the full regimen of therapy and probably at greater dosages.
The current study was designed to determine liver toxicity induced by combination of thalidomide and carboplatin via inflammation mediator parameter, nuclear factor kappa B (NF-kB), liver apoptotic marker parameter, cysteine aspartic acid specific protease (caspase-3), gene expression parameters, proliferator-activated.